NONALCOHOLIC STEATOHEPATITIS (NASH)
Clinical trials for NONALCOHOLIC STEATOHEPATITIS (NASH) explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS (NASH) trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS (NASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug targets liver fat in MASH patients
Disease control Recruiting nowThis early-stage study tests whether the drug miricorilant can lower the amount of fat the liver produces in people with MASH, a serious fatty liver condition. Eight adults with MASH will take the drug for 6 weeks, and researchers will measure changes in liver fat production and …
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 26, 2026 06:34 UTC
-
New drug shows promise for fatty liver in early trial
Disease control Recruiting nowThis study tests a drug called ADI-PEG 20 for people with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease. About 60 adults with confirmed NASH will receive either the drug or a placebo for 24 weeks. The main goal is to see if the drug reduces liver fat measured…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Polaris Group • Aim: Disease control
Last updated May 26, 2026 06:30 UTC